NCT00427791View on ClinicalTrials.gov

Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Leukemia
Interventions
DRUG

Etoposide

60 mg/kg IV Daily Over 4 Hours for 1 Day

RADIATION

Total Body Irradiation

3 Gy Daily for 4 Days

DRUG

Rituximab

375 mg/m\^2 IV Weekly Over 4-8 Hours for 4 Weeks

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00427791 - Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter